Patient demographics and tumor characteristics

Characteristics	⁹⁹Tcm-Dx+BD (n=271)		ICG+BD (n=200)		P
Characteristics	n	Percentage (%)	n	Percentage (%)	P
Mean age at diagnosis, years					0.09
≤ 50	165	60.89	137	68.50
>50	106	39.11	63	31.50
Menopausal status					0.11
Pre-menopausal	160	59.04	133	66.50
Post-menopausal	111	40.96	67	33.50
BMI					0.27
<18.5	6	2.21	4	2.00
18.5–24.9	182	67.16	148	74.00
≥25	83	30.63	48	24.00
Tumor side					0.62
Left	136	50.18	105	52.50
Right	135	49.82	95	47.50
Quadrant					0.37
Upper outer	164	60.52	111	55.50
Lower outer	32	11.81	24	12.00
Upper inner	55	20.30	40	20.00
Lower inner	12	4.43	12	6.00
Nipple-areolar area	8	2.95	13	6.50
Adjuvant chemotherapy					0.08
Yes	23	8.49	27	13.50
No	248	91.51	173	86.50
Surgical procedure					0.51
SLN	209	77.12	149	74.50
SLN+ALND	62	22.88	51	25.50
Histological type					0.67
Invasive ductal	216	79.70	166	83.00
Invasive lobular	5	1.85	2	1.00
In situ	34	12.55	24	12.00
Other	16	5.90	8	4.00
pT stage					0.43
Tis	32	11.81	19	9.50
T1	95	35.06	84	42.00
T2	141	52.03	94	47.00
T3	3	1.11	3	1.50
pN stage					0.22
N0	204	75.28	146	73.00
N1	56	20.66	44	22.00
N2	9	3.32	4	2.00
N3	2	0.74	6	3.00
pTNM					0.43
0	31	11.44	18	9.00
I	76	28.04	67	33.50
II	152	56.09	103	51.50
III	12	4.43	12	6.00
ER					0.60
Positive	210	77.49	159	79.50
Negative	61	22.51	41	20.50
PR					0.32
Positive	202	74.54	157	78.50
Negative	69	25.46	43	21.50
HER2					0.60
Positive	57	21.03	46	23.00
Negative	214	78.97	154	77.00
Ki-67					0.70
<14%	127	46.86	90	45.00
>14%	144	56.69	110	55.00

ICG: indocyanine green; BD: blue dye; BMI: body mass index; p: pathological; SLN: sentinel lymph node biopsy; ALND: axillary lymph node dissection; ER: estrogen receptors; PR: progesterone receptors; HER2: human epidermal growth factor receptor 2